Response of the Benign Hypertrophied Prostate to Treatment with an LHRH Analogue
- 31 July 1988
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 62 (2) , 163-165
- https://doi.org/10.1111/j.1464-410x.1988.tb04299.x
Abstract
Twenty patients with outflow tract obstruction secondary to benign prostatic hypertrophy were treated with an LHRH analogue, buserelin, for up to 6 months. Despite maintaining castrate leaves of testosterone and achieving a significant reduction in tissue levels of dihydrotestosterone, no significant improvement was seen in flow rate or residual volume.This publication has 7 references indexed in Scilit:
- Bifluranol in the treatment of benign prostatic hyperplasia (BPH)The Prostate, 1985
- The clinical significance of steroid hormone measurements in the management of patients with prostatic cancerWorld Journal of Urology, 1983
- The pathogenesis of benign prostatic hyperplasiaThe American Journal of Medicine, 1980
- The Treatment of Benign Prostatic Hypertrophy with Flutamide (SCH 13521): A Placebo-Controlled StudyJournal of Urology, 1975
- Medrogestone: A Prospective Study in the Pharmaceuticalmanagement of Benign Prostatic HyperplasiaJournal of Urology, 1975
- The Incidence of Benign Prostatic ObstructionJournal of Urology, 1968
- THE RESULTS OF DOUBLE CASTRATION IN HYPERTROPHY OF THE PROSTATEAnnals of Surgery, 1895